Editas Medicine (EDIT) vs Rezolute (RZLT)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Editas Medicine (EDIT) has outperformed Rezolute (RZLT) over the past year, losing 30.0% versus a loss of 50.0%. Over five years, RZLT leads with a -34.1% price change compared with -92.8% for EDIT. Rezolute is the larger company by market cap ($448.8 million vs $436.2 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | EDIT | RZLT |
|---|---|---|
| Share price | $2.84 | $4.64 |
| Market cap | $436.17M | $448.79M |
| 1-day change | +3.27% | +5.94% |
| YTD return | +34.15% | +85.59% |
| 1-year return | -30.03% | -50.00% |
| 5-year return | -92.77% | -34.14% |
| EPS (TTM) | $-0.68 | $-0.75 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $4.33 | $11.46 |
| 52-week low | $1.66 | $1.07 |
| Distance from 52-week high | -34.41% | -59.50% |
| Analyst consensus | buy | strong_buy |
| Avg. price target upside | +107.75% | +111.21% |
| Average volume | 2.47M | 1.48M |
| Shares outstanding | 153.58M | 96.72M |
| Employees | 87 | 58 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- EDIT has outperformed RZLT by 20.0 percentage points over the past year.
About Editas Medicine
EDIT stock →Editas Medicine, Inc., a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases. The company develops a proprietary gene editing platform based on CRISPR technology.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 87 employees
About Rezolute
RZLT stock →Rezolute, Inc., a late-stage rare disease company, focuses developing therapies that treat refractory and debilitating hypoglycemia associated with various forms of hyperinsulinism (HI) in the United States. Its lead clinical asset is ersodetug, an intravenously administered human monoclonal antibody which is in Phase 3 clinical trial to treat tumor HI indication, as well as congenital HI.
Health Care · Biotechnology: Pharmaceutical Preparations · 58 employees
EDIT vs RZLT FAQ
Which is bigger, Editas Medicine or Rezolute?
Rezolute (RZLT) is larger, with a market capitalization of $448.79M compared with $436.17M for Editas Medicine (EDIT).
Which stock has performed better over the past year, EDIT or RZLT?
EDIT returned -30.03% over the past 12 months, compared with -50.00% for RZLT (price return, excluding dividends). Past performance does not predict future results.
Are Editas Medicine and Rezolute in the same industry?
Both are in the Health Care sector, but in different industries: Biotechnology: Biological Products (No Diagnostic Substances) for Editas Medicine and Biotechnology: Pharmaceutical Preparations for Rezolute.